Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
EGRX

EGRX - Eagle Pharmaceuticals Inc-DE Stock Price, Fair Value and News

$0.470.00 (0.00%)
Market Closed

86/100

EGRX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

86/100

EGRX

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

EGRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

EGRX Price Action

Last 7 days

8.6%

Last 30 days

38.2%

Last 90 days

88%

Trailing 12 Months

-76.0%

EGRX RSI Chart

EGRX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

EGRX Valuation

Market Cap

4.9M

Price/Earnings (Trailing)

0.41

Price/Sales (Trailing)

0.02

EV/EBITDA

1.44

Price/Free Cashflow

-0.53

EGRX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

EGRX Fundamentals

EGRX Revenue

EGRX Earnings

EGRX Profitability

Free Cashflow Yield

-190.31%

EGRX Investor Care

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023267.0M257.6M00
2022246.2M272.2M298.2M316.6M
2021183.0M189.2M179.1M171.5M
2020192.1M177.4M186.1M187.8M
2019216.5M213.9M203.7M195.9M
2018206.5M215.7M204.0M213.3M
2017236.7M245.9M271.1M236.7M
201659.5M94.4M126.5M189.5M
201550.5M50.7M53.6M66.2M
201420.2M20.9M19.1M19.2M
20136.3M10.0M13.7M17.7M
2012002.5M0
Get all data in R, Python etc through our Historical Stock Data APIs

About Eagle Pharmaceuticals Inc-DE

EGRX
Eagle Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also include EP-4104, a dantrolene sodium to treat organophosphate exposure; PEMFEXY, a ready-to-use/dilute liquid form of pemetrexed for non-small cell lung cancer and mesothelioma; EA-114 (fulvestrant) for HR+/HER- breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has license and collaboration agreements with Combioxin, SA for the development and commercialization rights to CAL02, an antitoxin agent for the treatment of severe pneumonia in combination with traditional antibacterial drugs; and AOP Orphan Pharmaceuticals GmbH for the commercial rights of Landiolol, a novel therapeutic product candidate for the short-term reduction of ventricular rate in patients with supraventricular tachycardia, including atrial fibrillation and atrial flutter. It has a strategic collaboration with Tyme Technologies, Inc. for the development of SM-88 to treat breast cancer (HR+/HER2-) and high-risk metastatic sarcomas. Eagle Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Woodcliff Lake, New Jersey.
 CEO
 WEBSITEeagleus.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers Specialty & Generic
 EMPLOYEES134

Eagle Pharmaceuticals Inc-DE Frequently Asked Questions

EGRX is the stock ticker symbol of Eagle Pharmaceuticals Inc-DE. Every public company that trades on a stock exchange gets a ticker symbol.

As of Thu Apr 30 2026, market cap of Eagle Pharmaceuticals Inc-DE is 4.94 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Thu Apr 30 2026, EGRX's PE ratio (Price to Earnings) is 0.41 and Price to Sales (PS) ratio is 0.02. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. EGRX PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Eagle Pharmaceuticals Inc-DE has provided -0.358 (multiply by 100 for percentage) rate of return.